Search

2024 NOV 1 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Autoimmune Diseases and Conditions - Psoriatic Arthritis. According [...]

2024 OCT 4 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on psoriatic arthritis are presented in a new report. According to [...]

? First study of Allocetra[sup.TM] in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis[sup.1], and has [...]

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody [sup. (R) ] sonelokimab in Psoriatic Arthritis Builds upon [...]

(GLOBE NEWSWIRE via COMTEX) -- MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody(R) sonelokimab in Psoriatic Arthritis [...]

LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]

The article discusses the challenges in diagnosing and managing psoriatic arthritis (PsA), a severe and debilitating disease that affects approximately 6.4 million people in Europe. PsA is difficult to diagnose due to the lack of specific diagnostic criteria or laboratory tests, and the disease course and response to treatment can be unpredictable. To address these challenges, the HIPPOCRATES research consortium was created, aiming to identify disease markers, develop prediction strategies, monitor disease progression, and identify personalized treatment options for PsA. The consortium involves collaboration between clinicians, researchers, and patients, and has received funding from the EU Innovative Medicines Initiative. The article emphasizes the importance of a multidisciplinary approach and patient involvement in the research. The consortium is also sharing data and conducting a prospective observational study to gather clinical data and blood samples from psoriasis patients across Europe. The ultimate goal is to develop tools for early diagnosis and prevention of PsA. The article highlights the progress made by the HIPPOCRATES projects and emphasizes the importance of disseminating the research findings and implementing them into everyday practice. [Extracted from the article]

2024 AUG 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on psoriatic arthritis. According to news reporting from Bath, [...]

2024 JUL 12 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on psoriatic arthritis have been published. According to news reporting [...]

M2 EQUITYBITES-June 13, 2024-UCB presents bimekizumab two-year data for axial spondyloarthritis and psoriatic arthritis (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk UCB, a Belgium-based global biopharmaceutical company, announced on Wednesday the first presentation [...]

M2 PHARMA-June 13, 2024-UCB presents bimekizumab two-year data for axial spondyloarthritis and psoriatic arthritis (C)2024 M2 COMMUNICATIONS UCB, a Belgium-based global biopharmaceutical company, announced on Wednesday the first presentation of [...]

Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust [...]

A recent study published in The Journal of the American Academy of Dermatology found that patients with psoriasis who received systemic therapy with biologics had a reduced risk of mortality compared to those who did not receive this treatment. The study, conducted in Canada, analyzed data from a large retrospective registry of psoriasis cases and controls. The researchers found that comorbidities such as hepatic injury, cardiovascular disease, and psychiatric affective disorders were strongly associated with mortality in psoriasis patients. However, the use of biologic agents was associated with higher survival rates, even after adjusting for comorbidity burden. The study suggests that systemic immunomodulatory agents may help improve patient survival, although further research is needed to establish a causal relationship. [Extracted from the article]

The article discusses the updated recommendations for managing psoriatic arthritis (PsA) by European Alliance of Associations for Rheumatology (EULAR). It emphasize safety considerations, particularly regarding the use of Janus kinase (JAK) inhibitors; the importance of considering nonmusculoskeletal manifestations in treatment decisions; and the use of systemic glucocorticoids as adjunctive therapy.

The article discusses that patients treated with dupilumab for atopic dermatitis experience musculoskeletal symptoms, including enthesitis, arthritis and tenosynovitis. These symptoms resemble those seen in psoriatic arthritis and peripheral spondyloarthritis; clinicians have been managing them with conservative approaches like adjusting the frequency of dupilumab administration; and important for prescribers to be aware of these potential side effects and monitor patients accordingly.

2024 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- According to news reporting based on a preprint abstract, our journalists obtained the [...]

2024 MAY 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on psoriatic arthritis is the subject of a new report. According [...]

2024 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Autoimmune Diseases and Conditions - Psoriatic Arthritis have been published. According [...]

2024 MAR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on psoriatic arthritis have been presented. According to news originating from [...]

2024 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on psoriatic arthritis have been presented. According to news reporting from Oregon Health [...]

2024 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on psoriatic arthritis. According to news originating from Rotterdam, [...]

A recent study presented at the American College of Rheumatology's annual meeting found that patients with early oligoarticular psoriatic arthritis (PsA) who took apremilast (Otezla) had a higher response rate compared to those who took a placebo. The study, called FOREMOST, showed that by 16 weeks, 33.9% of patients who received apremilast met the trial's primary outcome, which required attainment of 1 or fewer swollen and/or tender joints plus three of five additional criteria. The findings support the use of apremilast in mild PsA cases, and the drug is generally well-tolerated with a good safety profile. However, it is important to note that apremilast is an expensive medication compared to alternatives like methotrexate. [Extracted from the article]

The FDA has granted new indications for the use of upadacitinib (Rinvoq) in pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) who cannot tolerate or achieve adequate disease response with tumor necrosis factor (TNF) blockers. Upadacitinib is now available as a weight-based oral solution for the youngest patients in addition to tablets. The drug's safety in pediatric patients is similar to its safety profile in adults, but its safety and effectiveness for patients younger than 2 years old are unknown. Upadacitinib is also being studied for various other conditions in phase 3 trials. [Extracted from the article]

THOUSAND OAKS: Amgen has issued the following news release: Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla(r) (apremilast) in patients with early oligoarticular psoriatic [...]

(GLOBE NEWSWIRE via COMTEX) -- MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody(R) sonelokimab in active psoriatic arthritis - First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using [...]

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody [sup. (R) ] sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody[sup.(R)] to [...]

M2 PRESSWIRE-October 31, 2023-: Create a personalized and bespoke education experience! - The latest feature on the Psoriasis and Psoriatic Arthritis Hub (C)1994-2023 M2 COMMUNICATIONS RDATE:31102023 Unlock the full potential [...]

Description A type of arthritis that affects some people who have the skin condition psoriasis. Overview Psoriatic arthritis happens when the immune system attacks healthy cells and tissue. This causes [...]

The researchers found that 51 patients developed PsA during the 1-year follow-up, and 71 developed PsA during the 5-year follow-up. A new predictive tool known as the Psoriatic Arthritis Risk Estimation Tool (PRESTO) is now available to help clinicians estimate the risk of psoriatic arthritis (PsA) in their patients with psoriasis. [Extracted from the article]

The article discusses the increased risk of interstitial lung disease (ILD) in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). It discuses who are using biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs); risk of ILD in PsA patients and a higher risk in RA patients who were starting b/tsDMARDs compared to the general population and also mentions that methotrexate use did not appear to be associated with increased ILD risk in either disease.

A recent study examined the factors that contribute to fatigue in patients with psoriasis and psoriatic arthritis (PsA). The researchers used data from the Danish Skin Cohort and found that joint pain and itch were major drivers of fatigue in these patients, rather than the severity of their skin condition. The study highlights the importance of a symptom-based approach when treating psoriasis, rather than solely focusing on objective measures of severity. However, the study had limitations, such as not being able to determine whether the pain was inflammatory or noninflammatory and lacking information about the use of methotrexate, which can cause fatigue. [Extracted from the article]

Wilmington, Delaware, United States: Transparency Market Research has issued the following news release: The global psoriatic arthritis therapeutics market stood at USD 10.8 billion in 2021, and the global market [...]

New Brunswick, New Jersey: Johnson & Johnson has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS [...]

2023 NOV 29 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Autoimmune Diseases and Conditions - Psoriatic Arthritis. According to news [...]

2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Autoimmune Diseases and Conditions - Psoriatic Arthritis have been [...]

2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators publish new report on psoriatic arthritis. According to news originating from Selangor, [...]

2023 SEP 13 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on psoriatic arthritis have been published. According to news originating from Portland, [...]

A recent study conducted in Vienna found that nearly 70% of patients with hand osteoarthritis (OA) had tendon involvement, but this did not significantly impact hand function or pain. The study used ultrasonography to assess tendon damage and tenosynovitis in 86 patients with hand OA and compared them to a control group. The results showed that tendon damage was more common in the flexor tendons, while tenosynovitis was more prevalent in the extensor tendons. The study suggests that physicians should consider the high prevalence of tendon involvement in hand OA and perform sonographic examinations if there is clinical suspicion. However, the study had limitations, such as the lack of a standardized clinical examination and a preferred method for detecting tendon damage. [Extracted from the article]

A recent study conducted in Vienna found that nearly 70% of patients with hand osteoarthritis (OA) had tendon involvement, but this did not significantly impact hand function or pain. The study used ultrasonography to assess tendon damage and tenosynovitis in 86 patients with hand OA and compared them to a control group. The results showed that tendon damage was more common in the flexor tendons, while tenosynovitis was more prevalent in the extensor tendons. The study suggests that physicians should consider the high prevalence of tendon involvement in hand OA and perform sonographic examinations if there is clinical suspicion. However, the study had limitations, such as the lack of a standardized clinical examination and a preferred method for detecting tendon damage. [Extracted from the article]

The Food and Drug Administration (FDA) has approved ustekinumab-ttwe (Pyzchiva) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. The FDA has provisionally determined that Pyzchiva may be interchangeable with the reference product, but this designation will not take effect until the exclusivity period for the first approved biosimilar, ustekinumab-auub (Wezlana), expires. Pyzchiva is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. It will be commercialized by Sandoz in the United States and is expected to launch in February 2025. [Extracted from the article]

A database analysis found that rates of major adverse cardiovascular events (MACE) do not significantly differ among individual biologics used for psoriasis or psoriatic arthritis (PsA). The study included 32,758 patients treated with different biologics, and there was no difference in the incidence of MACE events in the different biologic groups. The study suggests that prescribers should not favor any one biologic class over another in terms of MACE risk. However, the study's retrospective nature and the limited generalizability of the patient population from Wisconsin are limitations. [Extracted from the article]

UCB, a global biopharmaceutical company, announced on 31 May 2023 new long-term 52-week data from three Phase 3 studies - BE COMPLETE with its long-term extension study, BE MOBILE 1 and BE MOBILE 2 - evaluating the efficacy and safety profile of bimekizumab, an inhibitor of IL-17F in addition to IL-17A, in adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) and active ankylosing spondylitis (AS), also known as radiographic axSpA (r-axSpA), respectively. These results from the bimekizumab phase 3 programme in PsA and axSpA are being presented at the European Congress of Rheumatology, EULAR 2023, in Milan, Italy, 31 May 2023-3 Jun 2023. The safety and efficacy of bimekizumab in PsA, nr-axSpA and r-axSpA have not been established, and it is not approved for use in PsA, nr-axSpA or AS by any regulatory authority worldwide. Bimekizumab 52-week PsA data: patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR): Key 52-week results from the BE COMPLETE open-label extension study (BE VITAL) are shared below and build on the previously announced 16-week results from the BE COMPLETE study and 52-week results from the BE OPTIMAL study. American College of Rheumatology (ACR) 50: At week 52, 51.7% of psoriatic arthritis patients (TNFi-IR) continuously treated with bimekizumab [160 mg every four weeks (Q4W); n=267], and 40.6% of patients who switched from placebo to bimekizumab at week 16 (n=133) achieved ACR50. Complete skin clearance (PASI100): At week 52, in patients with baseline psoriasis greater than or equal to 3% body surface area, 65.9% of patients continuously treated with bimekizumab (n=176) and 60.2% of patients who switched from placebo to bimekizumab at week 16 (n=88) achieved complete skin clearance (PASI100). Minimal disease activity (MDA): At week 52, 47.2% (n=126/267) of patients continuously treated with bimekizumab and 33.1% (n=44/133) of patients who switched from placebo to bimekizumab achieved MDA. Over 52 weeks, 62.6% (n=243/388) of patients treated with bimekizumab had greater than or equal to 1 treatment emergent adverse event (TEAE) and 5.9% (n=23/388) reported a serious TEAE. Candida infections were reported by 6.4% (n=25/388) of patients receiving bimekizumab with all cases reported as mild or moderate and none reported as systemic. Bimekizumab 52-week axSpA data: inflammation of the sacroiliac joints and spine and peripheral manifestations: Key 52-week results from the phase 3 BE MOBILE 1 and BE MOBILE 2 studies evaluating the effect of bimekizumab on inflammatory lesions of the sacroiliac joints (SIJ) and spine as measured objectively by magnetic resonance imaging (MRI), and on the main peripheral manifestations of axSpA are shared below and build on previously announced 16-week and 52-week results from BE MOBILE 1 and BE MOBILE 2. Inflammation SIJ: At week 52, in the BE MOBILE 1 imaging sub-study, 80.0% (n=32/40) of patients with inflammation at baseline receiving continuous bimekizumab and 57.1% (n=20/35) who switched from placebo to bimekizumab at week 16 achieved remission in inflammatory lesions of the SIJs [Spondyloarthritis Research Consortium of Canada (SPARCC SIJ less than 2)]. Original source: UCB, website: http://www.ucb.com/, Copyright UCB SA 2023., research and development; antiarthritics; bimekizumab; monoclonal antibodies; therapeutic antibodies; [...]

The Janssen Pharmaceutical Companies of Johnson & Johnson announced on 31 May 2023 new data from the Phase 3b COSMOS clinical trial showing that treatment with Tremfya (guselkumab) provided sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumour necrosis factor inhibitors (TNFi-IR). In a separate post-hoc analysis of the Phase 3 DISCOVER-1 and DISCOVER-2b clinical trial findings, Tremfya was shown to be associated with prompt and sustained improvements in all identified determinants. This analysis also identified factors that influenced disagreement between patient and physician global assessments (GA), such as patient-reported pain, physical aspects of health-related quality of life and fatigue. Tremfya is the first and only fully human selective interleukin (IL)-23 inhibitor therapy approved for the treatment of adult patients living with active PsA. These study results are among 41 company-sponsored abstracts being presented by Janssen at the 2023 Annual European Congress of Rheumatology (EULAR) meeting taking place in Milan, Italy, 31 May 2023-3 Jun 2023. A previous study has shown that sustained MDA is typically only achieved by a minority of patients receiving biologic therapy for active PsA. However, in a post-hoc analysis of the Phase 3b COSMOS clinical trial, Tremfya provided sustained improvement in all MDA domains from baseline through week 48 in adult patients living with active PsA and who were inadequate responders to one to two TNFis (n=189). Overall response rates at week 24 and week 48 were Psoriasis Area and Severity Index (PASI)c (66.8/81.5%), Leeds Enthesitis Index (LEI)d (74.5/79.8%), swollen joint count (SJC)e (46.2/63.0%), patient GA (24.5/39.9%), Health Assessment Questionnaire - Disability Index (HAQ-DI)f (26.1/37.0%), patient pain (14.7/30.6%) and tender joint count (TJC)e (14.7/28.3%), respectively. Physician-reported domains (LEI, PASI and SJC) were achieved faster than patient-driven domains (patient GA, HAQ-DI, patient pain and TJC). The importance of a personalized approach to PsA treatment that prioritizes shared decision-making and open dialogue is reinforced in a separate post-hoc analysis of the Phase 3 DISCOVER-1 and DISCOVER-2 studies, which identified differences between patient GA and physician GA. The results showed that while scores were aligned across most factors, patients weighed pain, fatigue and physical health higher than physicians. Tremfya was associated with prompt and sustained improvements in all identified determinants, including those driving higher patient versus physician scores, such as patient-reported pain, physical aspects of health-related quality of life, and fatigue. At baseline, patient GA and physician GA scores were similar in most instances (61.2%) with 23.2% of cases characterized by a patient GA score higher than a physician GA score. Higher patient scores meant the patient considered this aspect of their disease to be worse than the physician. 15.7% of cases had a physician GA score higher than patient GA. The proportion of patients with higher patient GA score than physician GA score increased to 39.1% at week 24, while the proportion with higher physician GA scores decreased to 11.2%. Original source: Johnson & Johnson, website: http://www.jnj.com/, Copyright Johnson & Johnson Services Inc 2023., research and development; antiarthritics; guselkumab; monoclonal antibodies; therapeutic antibodies; Tremfya; Janssen Pharmaceutical Companies; Johnson & [...]

THOUSAND OAKS: Amgen has issued the following news release: Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla(r) (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study [...]

Tenders are invited for supply of equipment to meet the needs of the research project entitled within the framework of the research project entitled 'iprolepsis/ psoriatic arthritis inflammation explained through [...]

LOS ANGELES: ACELYRIN, INC. has issued the following news release: ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]

At 46 weeks, izokibep demonstrated higher levels of response across psoriatic arthritis disease manifestations Long-term data build on statistically significant improvements demonstrated at 16 weeks across key measures of joint [...]

BRUSSELS: UCB has issued the following news release: UCB, a global biopharmaceutical company, today announced that it will present eight bimekizumab abstracts across a range of IL-17 mediated diseases1,2 - [...]